Galapagos Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Paul Stoffels

Chief Executive Officer (CEO)

€2.0m

Compensación total

Porcentaje del salario del CEO	38.0%
Permanencia del CEO	2.5yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.4yrs
Promedio de permanencia en la Junta Directiva	2.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paul Stoffels en comparación con los beneficios de Galapagos?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	€32m
Mar 31 2024	n/a	n/a	€31m
Dec 31 2023	€2m	€750k	-€4m
Sep 30 2023	n/a	n/a	-€153m
Jun 30 2023	n/a	n/a	-€46m
Mar 31 2023	n/a	n/a	-€69m
Dec 31 2022	€1m	€563k	-€71m

Compensación vs. Mercado: La compensación total ($USD2.19M) de Paul está en línea con el promedio de empresas de tamaño similar en el mercado UK ($USD2.14M).

Compensación vs. Ingresos: La compensación de Paul ha sido consistente con los resultados de la empresa en el último año.

CEO

Paul Stoffels (62 yo)

2.5yrs

Permanencia

€1,971,286

Compensación

Dr. Paulus A. Stoffels, also known as Paul, Ph.D. M.D. is Chief Executive Officer of Galapagos NV since April 01, 2022 and also serves as its Chairman since April 26, 2022 and also serves as its Interim He...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paulus Stoffels	CEO, Chairman	2.5yrs	€1.97m	sin datos
Thad Huston	Executive VP	1.3yrs	sin datos	sin datos
Sofie Van Gijsel	Head of Investor Relations	no data	sin datos	sin datos
Valeria Cnossen	Executive VP & General Counsel	2.8yrs	sin datos	sin datos
Marieke Vermeersch	Head of Corporate Communication	no data	sin datos	sin datos
Annelies Missotten	Executive VP & Chief Human Resources Officer	no data	sin datos	sin datos
Ellen Aar	Head of Development	no data	sin datos	sin datos
Philippe Alen	Senior VP & Head of Business Development	2.8yrs	sin datos	sin datos
Dirk De Naeyer	Head of Development Operations	no data	sin datos	sin datos
Alice Dietrich	Head of Medical Affairs	no data	sin datos	sin datos
Pierre Raboisson	Head of Small Molecules Discovery & Senior VP	2.3yrs	sin datos	sin datos
Patrik Ringblom	Head of Strategy & US Lead	less than a year	sin datos	sin datos

2.4yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0JXZ se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paulus Stoffels	CEO, Chairman	2.5yrs	€1.97m	sin datos
Simon Sturge	Independent Non-Executive Director	1.1yrs	€32.37k	0.00027% € 4.6k
Jerome Contamine	Lead Independent Non-Executive Director	2.5yrs	€150.00k	0.0015% € 26.2k
Andrew Dickinson	Non-Executive Non-Independent Director	less than a year	sin datos	sin datos
Linda Higgins	Non-Executive Non-Independent Director	5yrs	sin datos	sin datos
Susanne Schaffert	Non-Executive Independent Director	1.3yrs	€59.85k	0.00055% € 9.4k
Peter Guenter	Independent Non-Executive Director	5.5yrs	€115.00k	0.0030% € 51.7k
Elisabeth Svanberg	Independent Non-Executive Director	4.5yrs	€138.75k	0.0029% € 49.0k
Daniel Baker	Non-Executive Independent Director	2.5yrs	€117.36k	0.0015% € 25.9k

2.5yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de 0JXZ no se considera experimentada (2.3 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Galapagos Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Galapagos NV Announces Board Changes

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

High number of new directors

Galapagos NV Announces Board Changes

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Recent updates

Investor sentiment improves as stock rises 16%

Galapagos Announces FDA Clearance of IND Application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in Relapsed/Refractory Non-Hodgkin Lymphoma

Second quarter 2024 earnings released

Galapagos NV to Report Fiscal Year 2024 Results on Feb 12, 2025

First quarter 2024 earnings released: EPS: €0.36 (vs €0.35 in 1Q 2023)

Full year 2023 earnings released: €0.061 loss per share (vs €1.09 loss in FY 2022)

Galapagos NV Announces Board Changes

Full year 2023 earnings released: €0.06 loss per share (vs €3.32 loss in FY 2022)

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Third quarter 2023 earnings released: EPS: €0.39 (vs €0.33 in 3Q 2022)

High number of new directors

Galapagos NV Announces Board Changes

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus

New major risk - Revenue and earnings growth

Galapagos NV Revises Sales Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: €0.078 (vs €0.29 loss in 2Q 2022)

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress

First quarter 2023 earnings released: EPS: €0.35 (vs €0.20 loss in 1Q 2022)

Full year 2022 earnings released: €3.32 loss per share (vs €1.92 loss in FY 2021)

Full year 2022 earnings released: €3.32 loss per share (vs €1.92 loss in FY 2021)

Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care

Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors

Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Third quarter 2022 earnings released: EPS: €0.30 (vs €0.99 loss in 3Q 2021)

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies

Galapagos NV announced that it has received €3.07625 million in funding

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Second quarter 2022 earnings released: €0.29 loss per share (vs €0.98 loss in 2Q 2021)

Galapagos NV (ENXTAM:GLPG) entered into a definitive agreement to acquire Abound Bio, Inc. for $14 million.

Galapagos NV announced that it expects to receive €1.459507 million in funding

High number of new directors

First quarter 2022 earnings released: €0.20 loss per share (vs €0.20 loss in 1Q 2021)

Galapagos NV to Report Q3, 2022 Results on Nov 03, 2022

Galapagos NV Announces Executive Appointments

Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION Study in Patients with Moderate-To-Severe Ulcerative Colitis

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the European Crohn’s and Colitis Organization Annual Congress

Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Agency for Jyseleca (Filgotinib), as New Treatment for Ulcerative Colitis in Great Britain

Galapagos Nv Completes Patient Recruitment for Mangrove Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Third quarter 2021 earnings released: €0.64 loss per share (vs €1.25 loss in 3Q 2020)

Galapagos Announces Positive CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Second quarter 2021 earnings released: €0.98 loss per share (vs €1.80 loss in 2Q 2020)

Galapagos NV Demonstrates Early Clinical Activity with SIK2/3 Inhibition in Inflammation

Galapagos NV Announces That Primary and Secondary Endpoint Results from the Phase 3 SELECTIONinduction

Galapagos NV to Present Data on Rheumatoid Arthritis At the Upcoming European League Against Rheumatism (EULAR) Congress

Galapagos Announces First Patient Enrolled in FILOSOPHY Study to Advance Understanding of Jyseleca (Filgotinib) Effectiveness and Safety in A Real-World Setting

Galapagos Reports Primary Endpoint for the Ongoing Filgotinib MANTA and MANTA-RAy Safety Studies

Revenue beats expectations

Galapagos NV to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

New 90-day low: €73.62

Galapagos NV to Report Fiscal Year 2021 Results on Feb 24, 2022

NICE Recommends Galapagos Jyseleca (Filgotinib) on NHS in Decision for Rheumatoid Arthritis

Selvita S.A. (WSE:SLV) completed the acquisition of Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG).

Gilead Sciences, Inc. and Galapagos NV Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

New 90-day low: €98.00

Galapagos NV Reports Positive Topline Results with GLPG1205 in IPF Patients in PINTA Proof-of-Concept Trial